Abnormal Glucose Tolerance in Transfusion-Dependent β-Thalassemic Patients

Diabetes Care

Volumn 24, Issue 5, 2001, Pages 850-854

  Chern, Jimmy P S ^a   Lin, Kai Hsin ^b,c   Lu, Meng Yao ^b   Lin, Dong Tsam ^b   Lin, Kuo Sin ^b   Chen, Jong Dar ^a   Fu, Cheng Chung ^a  

^a Taoyuan Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON CHELATING AGENT;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD; BLOOD TRANSFUSION; CHILD; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HEPATITIS B; HEPATITIS C; HUMAN; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PREVALENCE; RISK FACTOR; TAIWAN;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; DIABETES MELLITUS; FEMALE; FERRITINS; GLUCOSE INTOLERANCE; HEPATITIS B; HEPATITIS C; HUMANS; IRON CHELATING AGENTS; MALE; PATIENT COMPLIANCE; PREVALENCE; RISK FACTORS; TAIWAN;

EID: 0035344276     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.5.850     Document Type: Article

References (36)

1. Cooley TB, Lee P: A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 37:29-30, 1925
2. Giardini C, Lucarelli G: Bone marrow transplantation in the treatment of thalassemia. Curr Opin Hematol I 170-176, 1994
3. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Pica A, Melevendi C, Di Gregorio F, Burattini MG. Terzoli S: Survival and causes of death in thalassemia major. Lancet 2:27-30, 1989
4. Borgna-Pignatti C, Rugolloto S, De Stefano P, Pica A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G: Survival and disease complications in thalassemia major. Ann N Y Acad Sci 850:227-231, 1998
5. Lassman MN, Genet M, Wise JK, Hendler R, Felig P: Carbohydrate homeostasis and pancreatic islet cell function in thalassemia. Ann Intern Med 80:65-69, 1974
6. Saudek CD, Hemm RM, Peterson CM: Abnormal glucose tolerance in β-thalassemia major. Metabolism 26:43-52, 1977
7. Gabutti V, Piga A: Results of long-term iron-chelating therapy. Acta Haematologica 95:26-36, 1996
8. Arrigo T, Crisafulli G, Meo A, Sturiale M, Lombardo F, Miceli M, Cucinotta D, De Luca F: Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major. J Pediatr Endocrinol Metab 11 (Suppl. 3):863-866, 1998
9. Gamberini MR, Fortini M, Gilli G, Testa MR. De Sanctis V: Epidemiology and chelation therapy effects on glucose homeostasis in thalassemia patients. J Pediatr Endocrinol Metab 11 (Suppl. 3):867-869, 1998
10. Italian Working Group on Endocrine Complications in Non-endocrine Diseases: Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol 42:581-586, 1995
11. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F: Insulin dependent diabetes in thalassemia. Arch Dis Child 63:58-62, 1988
12. Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, Tamborlane HA: Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Md 318:809-814, 1988
13. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
14. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
15. Ladis V, Theodorides C, Palamidou F, Frissiras S, Berdousi H, Kattamis C: Glucose disturbances and regulation with glibenclamide in thalassemia. J Pediatr Endocrinol Metab 11 (Suppl. 3):871-878, 1998
16. World Health Organization Expert Committee: Second Report on Diabetes Mellitus. Geneva. World Health Org., 1980 (Tech. Rep. Ser., no. 646)
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
18. Holl RW, Buck C, Cario H, Wolf A, Thon A, Kohne E, Debatin K-M: Diagnosis of diabetes in cystic fibrosis and thalassemia major. Diabetes Care 21:671-672, 1998
19. Ko TM, Hsu PM, Chen CJ, Hsieh FJ, Hsieh CY, Lee TY: Incidence study of heterozygous β-thalassemia in northern Taiwan. J Formos Med Assoc 88:678-681, 1989
20. Lin KH, Lin LL, Syi S, Lin KS: The incidence of β-thalassemia trait in Taiwan. Int J Pediatr Oncol 1:383-388, 1994
21. Ko TM, Xu X: Molecular study and prenatal diagnosis of α- and β- thalassemia in Chinese. J Formos Med Assoc 97:5-15, 1998
22. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567-573, 1994
23. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 331:574-578, 1994
24. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood 89:739-761, 1997
25. Olivieri NF: The β-thalassemias. N Engl J Med 341:99-109, 1999
26. Fernandez-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, Cabrero D, Fernandez-Castaner M, Soler J: Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 21:62-68, 1998
27. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T: High prevalence of diabetes mellitus among adult β-thalassemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 11:1033-1036, 1999
28. Kowdley KV, Kaplan MM: Iron-chelation therapy with oral deferiprone: toxicity or lack of efficacy? N Engl J Med 339:468-469, 1998
29. Piperno A, Fargion S, D'Alba R, Roffi L, Fracanzani AL, Vecchi L, Failla M, Fiorelli G: Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol 16:364-368, 1992
30. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B: Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 77:478-483, 1993
31. Rahier JR, Loozen S, Goebbels RM, Abrahem M: The haemochromatic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia 30:5-12, 1987
32. Costin G, Kogut MD, Hyman C, Ortega JA: Carbohydrate metabolism and pancreatic islet-cell function in thalassemia major. Diabetes 26:230-240, 1977
33. Lin KH, Lin KS, Feig SA: Marrow transplantation for thalassemia. Bone Marrow Transplant 1:115-120, 1986
34. Chen YC, Lin KH, Huang WS, Tang JL: Bone marrow transplantation in Taiwan: an overview. Bone Marrow Transplant 13: 705-708, 1994
35. Lin KH, Lin KS: Results of therapy for β-thalassemia major. J Formos Med Assoc 91:126-130, 1992
36. Cavallo-Perin P, Pacini G, Cerutti F, Bessone A, Condo C, Sacchetti L, Pica A, Pagano G: Insulin resistance and hyperinsulinemia in homozygous β-thalassemia. Metabolism 44:281-286, 1995